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Abstract 
High Pressure Liquid Chromatography (HPLC) method development plays an important role in the 
discovery, development and manufacture of pharmaceutical products and day to day quality work in the 
laboratory. This article focuses on the effective method development of HPLC. It highlights pertinent 
conditions and other important perspectives during method development.  A sequence of events required 
for effective method development is described. The steps involved in developing a stability-indicating 
HPLC method influences the analysis of degradation products/impurities in stability study and its 
validation demonstrate the suitability for its intended purpose. 
Keywords: Method development, High Pressure Liquid Chromatography (HPLC), analytes. 
 
1. Introduction 
Optimization of high pressure liquid chromatography (HPLC) method development has been discussed 
extensively in many standard textbooks and journals. However, most of the discussions have been focused 
on the optimization of HPLC conditions. This article will look at this topic from other perspectives.   All 
critical steps in method development will be summarized and sequence of events that required developing 
the method efficiently will be proposed. The steps will be discussed in the same order as they would be 
investigated during the method development process.  The rationale will be illustrated by focusing on 
developing a stability-indicating HPLC-UV method for related substances (impurities).  The principles, 
however, will be applicable to most other HPLC methods (Swartz 2002, Synder 1997) . 
 
In order to have an efficient method development process, the following three questions must be answered: 
 
1.1.  What are the critical components for a HPLC method? 
The 3 critical components for a HPLC method are: sample preparation, HPLC analysis and 
standardization (calculations).   During the preliminary method development stage, all individual 
components should be investigated before the final method optimization. This gives the scientist a 
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chance to critically evaluate the method performance in each component and streamline the final 
method optimization. 
 
1.2.  What should be the percentage of time spent on different steps of the method development? 
  The rest of the article will discuss the recommended sequence of events, and the development 
timeline.   One common mistake is that most scientists and researchers focus too much on the 
HPLC chromatographic conditions and neglect the other 2 components of the method (i.e., sample 
preparation, standardization).   The recommended timeline would help scientists investigate 
different aspects of the method development and allocate appropriate time in all steps. 
 
1.3.  How should a method development experiment be designed? 
   A properly designed method development experiment should consider the following important 
questions: 
      What sample should be used at each stage? 
      What should the scientists look for in these experiments? 
      What are the acceptance criteria? 
The authors will answer these questions in the following discussions. 
 
2. Method Development Timeline 
The following is a suggested method development timeline for a typical HPLC-UV related substance 
method. The percentage of time spent on each stage is proposed to ensure the scientist will allocate 
sufficient time to different steps.  In this approach, the three critical components for a HPLC method 
(sample preparation, HPLC analysis and standardization) will first be investigated individually.   Each of 
these steps will be discussed in more detail in the following paragraphs. 
Step 1: Define method objectives and understand the chemistry (10%) 
Determine the goals for method development (e.g., what is the intended use of the method?), and to 
understand the chemistry of the analytes and the drug product. 
 
Step 2: Initial HPLC condition (20%) 
Develop preliminary HPLC conditions to achieve minimally acceptable separations.   These HPLC 
conditions will be used for all subsequent method development experiments. 
 
Step 3: Sample preparation procedure (10%) 
Develop a suitable sample preparation scheme for the drug product 
 
Step 4: Standardization (10%) 
Determine the appropriate standardization method and the use of relative response factors in calculations. 
 
Step 5: Final method optimization/robustness (20%) 
Journal of Health, Medicine and Nursing    www.iiste.org 
ISSN 2422-8419 (Online) 
Vol . 12, 2015 
 
125 
Identify the “weaknesses” of the method and optimize the method through experimental design. Understand 
the method performance with different conditions, different instrument set ups and different samples. 
 
Step 6: Method validation (30%) 
Complete method validation according to ICH guidelines 
 
3. Define Method Objectives 
There is no absolute end to the method development process.    The question is “what is the ‘acceptable’ 
method performance”?   The acceptable method performance is determined by the objectives set in this 
step. This is one of the most important considerations often overlooked by scientists.   In this section, the 
different end points (i.e., expectations) will be discussed in descending order of significance. 
 
3.1 Analytes: 
For a related substance method, determining the “significant and relevant” related substances is very 
critical. With limited experience with the drug product, a good way to determine the significant related 
substances is to look at the degradation products observed during stress testing. Significant degradation 
products observed during stress testing should be investigated in the method development. 
Based on the current ICH guideline on specifications, the related substances method for a active 
pharmaceutical ingredients (API) should focus on both products should focus only on the synthetic 
impurities, while the same method for drug products should focus only on the degradation products. In 
general practice, unless there are any special toxicology concerns, related substances below the limit of 
qualification (LOQ) should not be reported and therefore should not be investigated. 
 
In this stage, relevant related substances should be separated into 2 groups: 
3.1.1. Significant related substances: Linearity, accuracy and response factors should be established for 
the significant related substances during the method validation. To limit the workload during method 
development, usually 3 or less significant related substances should be selected in a method. 
3.1.2. Other related substances: These are potential degradation products that are not significant in 
amount.   The developed HPLC conditions only need to provide good resolution for these related 
substances to show that they do not exist in significant levels. 
 
3.2 Resolution (Rs) 
A stability indicating method must resolve all significant degradation products from each other. Typically 
the minimum requirement for baseline resolution is 1.5. This limit is valid only for 2 Gaussian-shape peaks 
of equal size. In actual method development, Rs = 2.0 should be used as a minimum to account for day to 
day variability, non-ideal peak shapes and difference in peak sizes. 
 
3.3 Limit of Quantitation (LOQ) 
The desired method LOQ is related to the ICH reporting limits. If the corresponding ICH reporting limit is 
0.1%, the method LOQ should be 0.05% or less to ensure the results are accurate up to one decimal place. 
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However, it is of little value to develop a method with an LOQ much below this level in standard practice 
because when the method is too sensitive, method precision and accuracy are compromised. 
 
3.4 Precision, Accuracy 
Expectations for precision and accuracy should be determined on a case by case basis. For a typical related 
substance method, the RSD of 6 replicates should be less than 10%. Accuracy should be within 70% to 
130% of theory at the LOQ level. 
 
3.5 Analysis time 
A run time of about 5-10 minutes per injection is sufficient in most routine related substance analyses. 
Unless the method is intended to support a high-volume assay, shortening the run time further is not 
recommended as it may compromise the method performance other aspects (e.g., specificity, precision and 
accuracy.) 
3.6 Adaptability for Automation 
For methods that are likely to be used in a high sample volume application, it is very important for the 
method to be “automatable”. The manual sample preparation procedure should be easy to perform. This 
will ensure the sample preparation can be automated in common sample preparation workstations. 
 
4. Understand the Chemistry 
Most sample preparations involve the use of organic-aqueous and acid-base extraction techniques. 
Therefore it is very helpful to understand the solubility and pKa of the analytes. Solubility in different 
organic or aqueous solvents determines the best composition of the sample solvent. pKa determines the pH 
in which the analyte will exist as a neutral or ionic species. This information will facilitate an efficient 
sample extraction scheme and determine the optimum pH  in mobile phase to achieve good seperations. 
 
4.1 Chemical Properties 
Most sample preparation involves the use of organic-aqueous and acid-base extraction techniques. 
Therefore it is very helpful to understand the solubility and pKa of the analytes. Solubility in different 
organic or aqueous solvents determines the best composition of the sample solvent. pKa determines the pH 
in which the analyte will exist as a neutral or ionic species. This information will facilitate an efficient 
sample extraction scheme and determine the optimum pH in mobile phase to achieve good separations. 
 
4.2 Potential Degradation Products 
Subjecting the API or drug product to common stress conditions provides insight into the stability of the 
analytes under different conditions. The common stress conditions include acidic pH, basic pH, neutral pH, 
different temperature and humility conditions, oxidation, reduction and photo-degradation. These studies 
help to determine the significant related substances to be used in method development, and to determine the 
sample solvent that gives the best sample solution stability. 
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In addition, the structures of the analytes will indicate the potential active sites for degradation. Knowledge 
from basic organic chemistry will help to predict the reactivity of the functional groups. For example, some 
excipients are known to contain trace level of peroxide impurities.   If the analyte is susceptible to 
oxidation, these peroxide impurities could possibly produce significant degradation products (Fig 1). 
 
4.3 Sample Matrix 
Physical (e.g., solubility) and chemical (e.g., UV activity, stability, pH effect) properties of the sample 
matrix will help to design an appropriate sample preparation scheme. For example, Hydroxypropy1 
Methylcellulose (HPMC) is known to absorb water to form a very viscous solution, therefore it is essential 
to use mostly organic solvents in sample preparation. 
 
5. Initial Method Conditions 
The objective at this stage is to quickly develop HPLC conditions for subsequent method development 
experiments. A common mistake is that scientists spend too much time at this stage trying to get a perfect 
separation. 
5.1 Preliminary HPLC Conditions 
In order to develop preliminary HPLC conditions in a timely fashion, scientists should use artificial mixtures 
of active pharmaceutical ingredients and related substances at relatively high concentrations (e.g., 1-2% of 
related substance relative to API) to develop the preliminary HPLC conditions. This concentration ratio 
between API and the related substances should be maintained to ensure the chromatography represents that 
of a real sample. Alternatively, a highly stressed sample (e.g., 5% degradation) can also be used at this stage. 
With the known composition and high levels of degradation products in the sample, one can evaluate the 
chromatography to determine whether there are adequate separations for all analytes. The high 
concentrations of related substances are used to ensure all peaks will be detected. 
 
Computer assisted method development can be very helpful in developing the preliminary HPLC conditions 
quickly. Since the objective at this stage is to quickly develop HPLC conditions for subsequent method 
development experiments, scientists should focus on the separation of the significant related substances 
(section 3.1.1) instead of trying to achieve good resolution for all related substances. These significant 
related substances should be baseline resolved from each other with Rs > 2.0. After the preliminary method 
development, the HPLC conditions can be further specificity for the other related substances. 
 
5.2 Aged HPLC Column 
An aged HPLC column should be used to develop the initial HPLC conditions.   Usually it is more difficult 
to achieve the required resolution with an aged column (e.g., column with about 200 injections). This will 
reflect the worst case scenario likely to be encountered n actual method uses, and help the long-term method 
robustness. 
In general, develop all methods with HPLC columns from the same vendor. The preferred brand of HPLC 
column should be selected primarily based on the long term stability and lot to lot reproducibility. 
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6. Sample Preparation 
 
6.1.  Selection of Sample Solvent 
This stage focuses on the selection of the sample solvent (for extraction) and the proper sample preparation 
procedures. Investigate the effect of sample solvents of different % organic, pH, extraction volume and 
extraction procedure on accuracy, precision, sensitivity (LOQ) and the changes in the chromatography (e.g., 
peak shape, resolution). Whenever possible use the mobile phase in the sample preparation. This will ensure 
that there will not be any compatibility issues between the sample solution and the HPLC conditions. 
 
6.1.1 Accuracy: To investigate the accuracy in sample preparation (i.e., extraction efficiency), prepare a 
spiked solution by adding known amounts of related substances into a sample matrix. Compare 
responses of the spike solutions and the neat standard solutions to assess the recovery from the sample 
preparation. In this stage, since only one particular step is being investigated (i.e., sample preparation), 
close to theoretical recovery should be observed at this point (e.g., 90-110%). (Fig 2). 
 
6.1.2 Precision: Use the stressed sample to represent the worst case scenario and perform replicate sample 
preparations from the same composite. Investigate the consistency of the related substance profile (i.e., any 
missing peaks?) and the repeatability results from these preparations. 
 
6.2 Another objective is to determine the sample concentration that gives an acceptable LOQ (Signal to 
Noise ratio, S/N) in low level spike concentrations.  The sample concentration should be low enough to 
maintain linearity and precision, but high enough to achieve the desired LOQ. For example, if the ICH 
reporting limit for this drug product is 0.1%, the LOQ of the method should be less than 0.05% (i.e., desired 
LOQ, in %). By using spike sample solutions of very diluted concentrations for the significant related 
substances, estimate the concentrations that give a S/N of about 10 for significant related substances. This 
estimated concentration is the appropriate LOQ concentration (i.e., estimated LOQ concentration, in 
µg/mL). 
The following equation can be used to estimate the target sample concentration for the method: 
Target sample concentration = 
 estimated LOQ concentration (µg/mL) x 1/desired LOQ (%) x 100% 
 
7. Standardization  
 
7.1 Area % method 
If the response of the active pharmaceutical ingredient is linear from LOQ to the nominal sample 
concentration, use the % area approach where the related substance is reported as % area. This is the most 
straightforward approach, and doesn’t require the preparation of standard solutions. It also has the highest 
precision since preparation to preparation variation will not affect the results. However,  in order to ensure 
the concentration is linear within this range, the sample concentration is usually limited and this will reduce 
Journal of Health, Medicine and Nursing    www.iiste.org 
ISSN 2422-8419 (Online) 
Vol . 12, 2015 
 
129 
the method sensitively (i.e., increase LOQ). In general, use this approach as long as the desired LOQ can be 
achieved. 
 
7.2 External Standard method  
 Use the external standard method if the response of the active pharmaceutical ingredient is not linear 
throughout the whole range,  or the desired LOQ cannot be achieved by the area % method. The 
concentration of standard solution should be high enough to ensure the standard solution can be prepared 
accurately and precisely on a routine basis, it should be low enough to approximate the concentration of 
related substance in the sample solution.    In general,  the standard concentration should correspond to 
about 5% of related substances. 
 
7.3 Wavelength Selection and Relative Response Factor 
Generate the linearity plot of API and related substances at different wavelengths. At this point, Photodiode 
Array Detector can be used to investigate the linearity of the active pharmaceutical ingredient and related 
substances in the proposed concentration range.   By comparing the linearity slopes of the active 
pharmaceutical ingredient and the related substances, one can estimate the relative response factors of the 
related substances at different wavelengths. 
Disregard of whether Area % or External Standard approach is used, if the relative response factors of some 
significant related substances are far from unity,  a response factor correction must be applied. 
The optimum wavelength of detection is the wavelength that gives the highest sensitivity (λmax) for 
significant related substances and minimize the difference in response factors between those of the active 
pharmaceutical ingredient and the related substances. 
After the optimum wavelength is determined, use a highly stress sample (e.g., 5% degradation) to verify that 
the selected wavelength will give the highest % related substances results. 
 
7.4 Overall accuracy 
A final check of the method performance is to determine the overall accuracy of the method. Unlike the 
accuracy from sample preparation (section 6.1.1), which simply compares the response of the analyte with 
and without spiking with matrix, the overall accuracy compares the % related substances calculated from an 
accuracy solution with that of the theoretical value. The accuracy solutions are the solutions spiked with 
known concentrations of related substances and matrix. Since the extraction efficiency, choice of wavelength 
and the bias in standardization influence the calculated related substance result, this is the best way to 
investigate the accuracy of the method.  Overall accuracy reflects the true accuracy of the method. 
 
8. Method Optimization/Robustness 
After the individual components of the method are optimized, perform the final optimization of the method 
to improve the accuracy, precision and LOQ.   Use an experimental design approach to determine the 
experimental factors that have significant impact on the method. This is very important in determining what 
factors need to be investigated in the robustness testing during the method validation (see section 9). To 
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streamline the method optimization process, use Plackett Burmann Design (or similar approach to 
simultaneously determine the main effects of many experimental factors (Debebe et al). 
 
Some of the typical experimental factors that need to be investigated are: 
 HPLC conditions: % organic, pH, flow rate, temperature, wavelength, column age. 
 Sample preparation: % organic, pH, shaking/sonication, sample size, sample age. 
 Calculation/standardization: integration, wavelength, standard concentration, response  
factor correction. 
 
Typical responses that need to be investigated are: 
Results: precision (%RSD), % related substance of significant related substances, total related substances. 
Chromatography: resolution, tailing factor, separation of all related substances (section 3.1.1 and 3.1.2). 
 
9. Method validation 
9.1 Robustness 
Method validation should be treated as a “final verification” of the method performance and should not be 
used as part of the method development. Some of the typical method validation parameters should be studied 
thoroughly in the previous steps (Korany 2012). In some cases, robustness can be completed in the final 
method optimization before method validation.   At this point, the robustness experiments should be 
limited only to the most significant factors (usually less than 4 factors).  In addition, unlike the final method 
optimization (see section 8), the experimental factors should be varied within a narrow range to reflect 
normal day to day variation. During the method validation, the purpose is to demonstrate that the method 
performance will not be significantly impacted by slight variations of the method conditions. 
 
9.2 Linearity, Accuracy, Response Factor 
Linearity, accuracy and response factors should be established for the significant related substances (section 
3.1.1) during the method validation. In order to limit the workload of the method development, usually less 
than 3 significant related substances should be selected in a method. Therefore, the other related substances 
(section 3.1.2) should not be included in the experiments. 
 
 
9.3 System suitability criteria  
It is advisable to run system suitability tests in these robustness experiments.  During the robustness testing 
of the method validation, critical method parameter such as mobile phase composition and column 
temperature are varied to mimic the day-to-day variability. Therefore, the system suitability results from 
these robustness experiments should reflect the expected range. Consequently, the limits for system 




Journal of Health, Medicine and Nursing    www.iiste.org 
ISSN 2422-8419 (Online) 




All of the critical steps in method development have been summarized and prioritized. The steps for method 
development are discussed in the same order as they would be investigated in the actual method 
development process. These steps will ensure all critical method parameters are optimized before the method 
validation. 
 
In order to develop a HPLC method effectively, most of the effort should be spent in method development 
and optimization as this will improve the final method performance. The method validation, however, should 
be treated as an exercise to summarize or document the overall method performance for it intended purpose. 
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Figure 1:HPLC system with its different components 
FROM: Sighn R J Pharm Educ Res Vol. 4, Issue No. 1, June 2013 
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Figure 2: Graphical presentations of linearity plot of caffeine 
sample using HPLC. 
FROM: Sighn R J Pharm Educ Res Vol. 4, Issue No. 1, June 2013 
 
